NCT00871156已完成1 期
Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- TQ and Chloroquine (Day 2): AUC(0-tau), Cmax and Tmax
研究概览
简要总结
DDI study of Tafenoquine and Chloroquine
详细描述
Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and ECGs. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the Investigator and GSK medical monitor agree that the abnormality will not introduce additional risk factors and will not interfere with the study procedures.
- •Male or female between 18 and 55 years of age inclusive, at the time of signing the informed consent.
- •A female subject is eligible to participate if she is of non-childbearing potential or of child-bearing potential if has a negative urine pregnancy test at screening and Day -1, and agrees to use agreed upon contraception methods until 56 days after stopping study drug.
- •Body weight >=60 kg (132 pounds) and BMI within the range 19-32 kg/m2 (inclusive).
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form
排除标准
- •A positive urine drug/alcohol screen at screening or Day -
- •History or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
- •History of illicit drug abuse within 6 months prior to screening.
- •History of regular alcohol consumption within 6 months of the study
- •Subjects who are unwilling to comply with the lifestyle guidelines required.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- •History of sensitivity to any of the study medications or their components.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Pregnant females as determined by positive urine hCG test at screening or prior to dosing.
- •Lactating females.
- •Subject is mentally or legally incapacitated.
- •A positive HIV antibody, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- •The subject's systolic blood pressure is outside the range of 90-150mmHg or diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside the range of 50-100bpm for female subjects and 45-100bpm for male subjects at screening and Day -
- •Cardiac conduction abnormalities as specified inprotocol
- •Any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety for the individual subject.
- •History of angina, ischemic heart disease, myocardial infarction, or clinically significant arrhythmia.
- •History of epilepsy, convulsions or psychological disorders.
- •History of porphyria.
- •AST, ALT or alkaline phosphatase >1.5 times the upper limit of normal and/or total bilirubin level outside the normal range at screening. A single repeat is allowed for eligibility determination.
- •Documented Glucose-6-phosphate dehydrogenase (G6PD) deficiency, determined by a quantitative assay of enzyme activity.
- •History of hemoglobinopathy; or current or past history of methemoglobinemia or methemoglobin percentage above the reference range at screening.
- •History of previous eye surgery involving the retina, Lasik surgery within 90 days, or retinal/corneal abnormalities.
- •Any clinically significant abnormalities on the screening Humphrey 10-2 visual field test.
- •Best corrected visual acuity worse than 0.3 logMAR (20/40 Snellen equivalent) (i.e., 20/40 or better vision will be allowed on study).
研究组 & 干预措施
Part 2
Placebo Comparator
Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
干预措施: Placebo (Drug)
Part 1
Active Comparator
Tafenoquine + Chloroquine vs. Chloroquine alone
干预措施: Chloroquine, Tafenoquine (Drug)
Part 2
Placebo Comparator
Chloroquine alone, Tafenoquine alone or Chloroquine+Tafenoquine
干预措施: Chloroquine, Tafenoquine (Drug)
结局指标
主要结局
TQ and Chloroquine (Day 2): AUC(0-tau), Cmax and Tmax
时间窗: 56 days
CQ and TQ (Day 3): AUC(0-tau), AUC(0-inf), Cmax, Tmax and t1/2
时间窗: 56 days
AEs, vital signs, 12-lead ECGs, telemetry, clinical laboratory and ophthalmic assessments
时间窗: 56 days
次要结局
- QTcF, QT, QRS, RR and HR as assessed by 12-lead ECG(56 Days)
- Changes from baseline in QTcF(56 days)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease ProgressionCOVID 19 DiseaseMild to Moderate COVID 19 DiseaseSARS-CoV-2Infectious DiseaseSevere Acute Respiratory Syndrome Coronavirus 2NCT0594781260P Australia Pty Ltd148
暂停
3 期
Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum MalariaMalariaNCT00442403Université Victor Segalen Bordeaux 2200
已完成
4 期
Pharmacokinetic Study of Multi-dose ChloroquineMalariaNCT01814423Bandim Health Project30
已完成
2 期
Tafenoquine in Patients With Mild to Moderate COVID-19COVID 19 DiseaseNCT0453334760 Degrees Pharmaceuticals LLC86
已完成
3 期
Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in ChildrenP. Falciparum MalariaNCT01082705Centers for Disease Control and Prevention323